High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Laura Kohtamäki; Mariliina Arjama; Siru Mäkelä; Philipp Ianevski; Katja Välimäki; Susanna Juteau; Suvi Ilmonen; Daniela Ungureanu; Olli Kallioniemi; Astrid Murumägi; Micaela Hernberg

doi:10.1016/j.tranon.2021.101290

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

Laura Kohtamäki, Mariliina Arjama, Siru Mäkelä, Philipp Ianevski, Katja Välimäki, Susanna Juteau, Suvi Ilmonen, Daniela Ungureanu, Olli Kallioniemi, Astrid Murumägi, Micaela Hernberg

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Artikelnummer	101290
Tidskrift	Translational oncology
Volym	15
Nummer	1
Antal sidor	11
ISSN	1936-5233
DOI	https://doi.org/10.1016/j.tranon.2021.101290
Status	Publicerad - jan. 2022
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.1016/j.tranon.2021.101290

1-s2.0-S1936523321002813-mainSlutlig publicerad version, 5,72 MBLicens: CC BY

Citera det här

Kohtamäki, L., Arjama, M., Mäkelä, S., Ianevski, P., Välimäki, K., Juteau, S., Ilmonen, S., Ungureanu, D., Kallioniemi, O., Murumägi, A., & Hernberg, M. (2022). High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Translational oncology, 15(1), Artikel 101290. https://doi.org/10.1016/j.tranon.2021.101290

@article{c31e3d3e366a43699ff37aea731696e9,

title = "High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma",

keywords = "Malignant melanoma, Drug testing, Kinase inhibitors, Targeted therapy, NRAS, Personalized therapy, PI3K INHIBITOR GDC-0941, MUTANT MELANOMA, MEK INHIBITION, COMBINED BRAF, DOUBLE-BLIND, SENSITIVITY, MUTATIONS, KIT, MULTICENTER, DABRAFENIB, 3122 Cancers",

author = "Laura Kohtam{\"a}ki and Mariliina Arjama and Siru M{\"a}kel{\"a} and Philipp Ianevski and Katja V{\"a}lim{\"a}ki and Susanna Juteau and Suvi Ilmonen and Daniela Ungureanu and Olli Kallioniemi and Astrid Murum{\"a}gi and Micaela Hernberg",

year = "2022",

month = jan,

doi = "10.1016/j.tranon.2021.101290",

language = "English",

volume = "15",

journal = "Translational oncology",

issn = "1936-5233",

publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",

number = "1",

}

Kohtamäki, L , Arjama, M, Mäkelä, S, Ianevski, P, Välimäki, K , Juteau, S , Ilmonen, S , Ungureanu, D , Kallioniemi, O , Murumägi, A & Hernberg, M 2022, 'High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma', Translational oncology, vol. 15, nr. 1, 101290. https://doi.org/10.1016/j.tranon.2021.101290

TY - JOUR

T1 - High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma

AU - Kohtamäki, Laura

AU - Arjama, Mariliina

AU - Mäkelä, Siru

AU - Ianevski, Philipp

AU - Välimäki, Katja

AU - Juteau, Susanna

AU - Ilmonen, Suvi

AU - Ungureanu, Daniela

AU - Kallioniemi, Olli

AU - Murumägi, Astrid

AU - Hernberg, Micaela

PY - 2022/1

Y1 - 2022/1

KW - Malignant melanoma

KW - Drug testing

KW - Kinase inhibitors

KW - Targeted therapy

KW - NRAS

KW - Personalized therapy

KW - PI3K INHIBITOR GDC-0941

KW - MUTANT MELANOMA

KW - MEK INHIBITION

KW - COMBINED BRAF

KW - DOUBLE-BLIND

KW - SENSITIVITY

KW - MUTATIONS

KW - KIT

KW - MULTICENTER

KW - DABRAFENIB

KW - 3122 Cancers

U2 - 10.1016/j.tranon.2021.101290

DO - 10.1016/j.tranon.2021.101290

M3 - Article

SN - 1936-5233

VL - 15

JO - Translational oncology

JF - Translational oncology

IS - 1

M1 - 101290

ER -